Exome-wide association study of treatment-resistant depression suggests novel treatment targets

Sci Rep. 2023 Aug 1;13(1):12467. doi: 10.1038/s41598-023-38984-z.

Abstract

Treatment-resistant depression (TRD) is a severe form of major depressive disorder (MDD) with substantial public health impact and poor treatment outcome. Treatment outcome in MDD is significantly heritable, but genome-wide association studies have failed to identify replicable common marker alleles, suggesting a potential role for uncommon variants. Here we investigated the hypothesis that uncommon, putatively functional genetic variants are associated with TRD. Whole-exome sequencing data was obtained from 182 TRD cases and 2021 psychiatrically healthy controls. After quality control, the remaining 149 TRD cases and 1976 controls were analyzed with tests designed to detect excess burdens of uncommon variants. At the gene level, 5 genes, ZNF248, PRKRA, PYHIN1, SLC7A8, and STK19 each carried exome-wide significant excess burdens of variants in TRD cases (q < 0.05). Analysis of 41 pre-selected gene sets suggested an excess of uncommon, functional variants among genes involved in lithium response. Among the genes identified in previous TRD studies, ZDHHC3 was also significant in this sample after multiple test correction. ZNF248 and STK19 are involved in transcriptional regulation, PHYIN1 and PRKRA are involved in immune response, SLC7A8 is associated with thyroid hormone transporter activity, and ZDHHC3 regulates synaptic clustering of GABA and glutamate receptors. These results implicate uncommon, functional alleles in TRD and suggest promising novel targets for future research.

Trial registration: ClinicalTrials.gov NCT00021528.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Depression
  • Depressive Disorder, Major* / drug therapy
  • Depressive Disorder, Major* / genetics
  • Exome / genetics
  • Genome-Wide Association Study
  • Humans
  • Nuclear Proteins / genetics
  • Protein Serine-Threonine Kinases / genetics
  • Treatment Outcome

Substances

  • STK19 protein, human
  • Nuclear Proteins
  • Protein Serine-Threonine Kinases
  • PYHIN1 protein, human

Associated data

  • ClinicalTrials.gov/NCT00021528